Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Time is of the essence in depressed diabetes patients

Time is of the essence in depressed diabetes patients

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Chronic nerve pain: an interview with Professor Sally Lawson

Chronic nerve pain: an interview with Professor Sally Lawson

RegeneRx’s Thymosin Beta 4 can promote recovery of diabetic peripheral neuropathy

RegeneRx’s Thymosin Beta 4 can promote recovery of diabetic peripheral neuropathy

Hemodialysis foot ulcer risk not confined to diabetes

Hemodialysis foot ulcer risk not confined to diabetes

Hemodialysis foot ulcer risk not confined to diabetes

Hemodialysis foot ulcer risk not confined to diabetes

NYUCN professor to investigate efficacy of Acu/Moxa in managing irritable bowel syndrome

NYUCN professor to investigate efficacy of Acu/Moxa in managing irritable bowel syndrome

Medical devices for diabetic peripheral neuropathy: an interview with Dr. Shai Gozani, CEO of NeuroMetrix

Medical devices for diabetic peripheral neuropathy: an interview with Dr. Shai Gozani, CEO of NeuroMetrix

Diabetes impairs women’s sex life

Diabetes impairs women’s sex life

Diabetes impairs women’s sex life

Diabetes impairs women’s sex life

Treatments for peripheral neuropathic pain compared

Treatments for peripheral neuropathic pain compared

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Diabetic women more likely to report low overall sexual satisfaction

Diabetic women more likely to report low overall sexual satisfaction

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress

LUMC oncologist presents survival data for brentuximab vedotin at 17th EHA Congress

Diabetic Neuropathy: An interview with Dr Brian Callaghan

Diabetic Neuropathy: An interview with Dr Brian Callaghan

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

Genentech's Perjeta helps people with HER2-positive metastatic breast cancer live longer

OSA independently linked with DPN in patients with type 2 diabetes mellitus

OSA independently linked with DPN in patients with type 2 diabetes mellitus

Cebix announces data from Ersatta Phase 1 study on type 1 diabetes

Cebix announces data from Ersatta Phase 1 study on type 1 diabetes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.